Try our Advanced Search for more refined results
BURLINGTON DRUG CO., INC. et al v. PFIZER INC. et al
Case Number:
3:12-cv-02389
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Baker & Hostetler
- Berger Montague
- Blank Rome
- Carella Byrne
- Cohen Milstein
- Cohn Lifland
- Connell Foley
- DeBenedictis & DeBenedictis
- Dilworth Paxson
- Duane Morris
- Ferraro Law Firm
- Garwin Gerstein
- Gerard Fox Law
- Glancy Prongay
- Grant & Eisenhofer
- Hach Rose Schirripa
- Hangley Aronchick
- Haug Partners
- Kenny Nachwalter
- Kirkland & Ellis
- Lite DePalma
- Marcus & Shapira
- Miller Shah LLP
- Napoli Shkolnik
- NastLaw
- Neal & Harwell
- Patunas Law
- Robbins Geller
- Saiber LLC
- Sauder Schelkopf
- Schnader Harrison
- Schoenefeld Law Firm LLC
- Seeger Weiss
- Shub & Johns
- Spiro Harrison
- Walsh Pizzi
- White & Case
Companies
- Cardinal Health Inc.
- CVS Health Corp.
- Daiichi Sankyo Co.
- Fraternal Order of Police
- Giant Eagle Inc.
- H‑E‑B LP
- International Brotherhood of Electrical Workers
- LifeWallet
- Meijer Inc.
- Pfizer Inc.
- Ranbaxy
- Rite Aid Corp.
- Rochester Drug Cooperative Inc.
- Safeway Inc.
- Supervalu Inc.
- The Kroger Co.
- Viatris Inc.
Sectors & Industries:
-
August 21, 2020
Berger Montague Drops Bankrupt Client In Lipitor Case
Berger Montague agreed to drop its representation of Rochester Drug Cooperative Inc. in antitrust litigation over the cholesterol drug Lipitor, following another drug wholesaler's assertion that Rochester's recently filed bankruptcy creates potential conflicts in the long-running case.
-
July 10, 2019
Disciplinary Action Omission Prompts Atty Admission Redo
The normally mundane process of admitting outside attorneys to participate in specific litigation in a jurisdiction to which they are not admitted got complicated for a prominent antitrust plaintiff's bar attorney who initially failed to report years-old disciplinary actions in his application to participate in a New Jersey case.
-
August 22, 2018
Pfizer Chips Away At State Claims In Lipitor Antitrust MDL
A New Jersey federal judge has found that state antitrust claims against Pfizer Inc. and Ranbaxy Inc. tied to sales of the blockbuster cholesterol medication Lipitor aren't preempted by federal patent law, but that several antitrust and consumer protection claims can be cut on other grounds.
-
May 15, 2018
3rd Circ. Already OK'd Lipitor State Claims, Health Plans Say
The Third Circuit has already cleared a group of health plans that paid for the blockbuster cholesterol medication Lipitor to bring antitrust litigation against Pfizer Inc. and Ranbaxy Inc. based on various state laws, so the drugmakers' bid to dismiss the claims is fruitless, the plans told a New Jersey federal court Monday.
-
April 17, 2018
Pfizer, Ranbaxy Look To Dump State Claims In Lipitor MDL
Pfizer Inc. and generic-drug maker Ranbaxy Inc. asked a New Jersey federal court Monday to quash state law claims in multidistrict litigation from a group of Lipitor buyers that say the companies participated in an illegal pay-for-delay scheme to keep a generic version of the cholesterol drug out of the market.
-
March 17, 2015
Lipitor Buyers Can't Update Pay-For-Delay Suit Again
A New Jersey judge refused Monday to let Lipitor purchasers once again amend their complaint accusing Pfizer Inc. of paying off Ranbaxy Laboratories Ltd. through a patent settlement to delay launching a generic version of the cholesterol drug.
-
October 31, 2014
Pfizer Ducks End-Payors' Lipitor Antitrust Claims
A New Jersey federal judge on Thursday dismissed antitrust claims brought by indirect buyers of Lipitor in multidistrict litigation alleging Pfizer Inc. and Ranbaxy Laboratories Ltd. entered an anti-competitive patent infringement settlement, ruling the buyers' suit, like a previously dismissed direct-purchaser suit, fails to state a claim.
-
October 28, 2014
Pfizer Says Lipitor Buyers Shouldn't Get To Redo Antitrust Suit
Pfizer Inc. and Ranbaxy Laboratories Ltd. urged a New Jersey federal court Monday to reject a bid by Lipitor purchasers to revive a pay-for-delay antitrust case over a patent settlement for the cholesterol drug, saying the buyers didn't deserve a fourth shot at the case.
-
September 29, 2014
Lipitor Plaintiffs Admit Pay-For-Delay Suit Doomed
Indirect purchasers of Lipitor on Friday admitted that a New Jersey federal judge's dismissal of a similar direct-purchaser action dooms their antitrust suit in a multidistrict litigation challenging an allegedly anti-competitive patent infringement settlement between Pfizer Inc. and Ranbaxy Laboratories Ltd.
-
September 22, 2014
Pfizer Pushes To Ax Rest Of Lipitor Pay-For-Delay Suit
Pfizer Inc. and Ranbaxy Laboratories Ltd. urged a New Jersey federal judge on Friday to toss indirect purchasers' antitrust suit in multidistrict litigation challenging a purportedly anti-competitive patent infringement settlement between the companies over Lipitor, saying the claims were doomed after a similar direct purchaser action was recently dismissed.
- ← Previous
- 1
- 2
- 3
- Next →